Heterocyclic macrolide pharmaceutical agent, a method of...

Organic compounds -- part of the class 532-570 series – Organic compounds – Nitrogen attached directly or indirectly to the purine ring...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S254100, C549S271000

Reexamination Certificate

active

07576204

ABSTRACT:
A compound represented by the following general formula (I):(I) wherein R7and R21are the same or different and each represents optionally substituted C2-22alkoxy, etc.; a pharmaceutically acceptable salt thereof or hydrates of the same. The compound (1) inhibits angiogenesis and inhibits the production of VEGF particularly under hypoxic conditions, which makes it useful as a remedy for solid cancer.

REFERENCES:
patent: 6712617 (2004-03-01), Detmar et al.
patent: 7026352 (2006-04-01), Mizui et al.
patent: 4-352783 (1992-12-01), None
patent: 4352783 (1992-12-01), None
patent: WO-00/75126 (2000-12-01), None
patent: WO-02/12533 (2002-02-01), None
patent: WO 02/060890 (2002-08-01), None
patent: WO-02/060890 (2002-08-01), None
patent: WO-03/099813 (2003-12-01), None
Seki-Asano, Mitsuko et al., “Isolation and Characterization of a New 12-Membered Macrolide FD-895”, J. Antibiot., 1994, vol. 47, No. 12, pp. 1395 to 1401.
Mitsuko Seki-Asano et al.; The Journal of Antibiotics; vol. 47, No. 12, pp. 1395-1401, 1994.
Bestmann, Hans Jurgen. Synthesis, 1989, vol. 6, pp. 419-423.
Bestmann, Jans Jurgen. Angew. Chem., 1983, vol. 95, No. 10, pp. 810-811.
Furstner, Alois et al. Efficient Total Syntheses of Resin Glycosides and Analogues by Ring-Closing Olefin Metathesis, J. Am. Chem. Soc., 1999, vol. 121, pp. 7814-7821.
Gunawardana, Geewananda, et al. J. Am. Chem. Soc. 1999, vol. 121, pp. 6092-6093.
Rohr, Jurgen. Angew Chem. Int. Ed., 2000, vol. 39, No. 16, pp. 2847-2849.
Kobayashi, Jun'ichi et al.Tetrahedron Letters, 1996, vol. 37, No. 9, pp. 1449-1450.
Hamberg, Mats. Lipids, 2000, vol. 35, No. 4, pp. 353-363.
Hamberg, Mats. Chem. Phys. Lipids, 1988, vol. 46, No. 4, pp. 235-243.
Ryuichi Morishita. “Recent Progress in Gene Therapy for Cardiovascular Disease”, Circ Journal, vol. 66, pp. 1077-1086.
Moon-Seok Cha, “Endogenous Production of Nitric Oxide by vascular Endothelial Growth Factor Down-Regulates Proliferation of Choriocarcinoma Cells”, Biochemical and Biophysical Research Communications, vol. 282, pp. 1061-1066.
Sakai et al., “Shinki ko-shuyo kassei busshitsu pladienolide ni kansuru kenkyu (1)-shinki 12-inkan macrolide pladeienolide B no tanri to kozo”, Japan Society for Bioscience, Biotechnology, and Agrochemistry, Taikai Koen Yoshishu, Mar. 2003, p. 123.
Akifumi et al., “Shinki ko-shuyo kassei busshitsu pladienolide ni kansuru kenkyu (2) VEGF sansei yokusei kassei o shihyo to shita pladienolide-rui no kozo kassei sokan”, Japan Society for Bioscience, Biotechnology, and Agrochemistry, Taikai Koen Yoshishu, Mar. 2003, p. 124.
Keiji et al., “Shinki ko-shuyo kassei busshitsu pladienolide ni kansuru kenkyu (3)- pladienolide-rui no yakuri kassei (in vitro, in vivo)”, Japan Society for Bioscience, Biotechnology, and Agrochemistry, Taikai Koen Yoshishu, Mar. 2003, p. 124.
Proceedings for 2003 Annual Meeting of Japan Society for Bioscience, Biotechnology, and Agrochemistry, pp. 123-124, (2003).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Heterocyclic macrolide pharmaceutical agent, a method of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Heterocyclic macrolide pharmaceutical agent, a method of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic macrolide pharmaceutical agent, a method of... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4102490

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.